136 related articles for article (PubMed ID: 31378916)
21. "Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD.
Vogelmeier C; Worth H; Buhl R; Criée CP; Lossi NS; Mailänder C; Kardos P
Int J Chron Obstruct Pulmon Dis; 2017; 12():487-494. PubMed ID: 28203072
[TBL] [Abstract][Full Text] [Related]
22. Compare the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease.
Saraç P; Sayıner A
Tuberk Toraks; 2016 Jun; 64(2):112-8. PubMed ID: 27481077
[TBL] [Abstract][Full Text] [Related]
23. Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?
Reddy CB; Kanner RE
Drugs Aging; 2007; 24(8):615-28. PubMed ID: 17702532
[TBL] [Abstract][Full Text] [Related]
24. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
25. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
26. Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study.
Chen YF; Cheng YC; Chou CH; Chen CY; Yu CJ
BMC Pulm Med; 2019 Dec; 19(1):233. PubMed ID: 31795986
[TBL] [Abstract][Full Text] [Related]
27. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study.
Kuyucu T; Güçlü SZ; Saylan B; Demir C; Senol T; Güner S; Koyuncu E; Ozen F; Oztürk S; Cangül Z; Ağanoğlu S; Ozkaya S; Ocak SC; Akkurt H; Intepe YS; Bayrak MG; Güler T; Bekçi TT; Soyyiğit S; Seyfettin S; Kula O; Akbay MO; Büyükgöze B; Asal G; Başlilar S; Oztürk O;
Tuberk Toraks; 2011; 59(4):328-39. PubMed ID: 22233302
[TBL] [Abstract][Full Text] [Related]
28. Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible?
van Schayck CP; van den Broek PJ; den Otter JJ; van Herwaarden CL; Molema J; van Weel C
JAMA; 1995 Jul; 274(2):161-4. PubMed ID: 7596005
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological management of stable COPD].
Rauscher H
Wien Med Wochenschr; 2005 Mar; 155(5-6):95-100. PubMed ID: 15884489
[TBL] [Abstract][Full Text] [Related]
30. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
Kerwin EM; Williams J
Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
[TBL] [Abstract][Full Text] [Related]
31. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Niewoehner DE; Rice K; Cote C; Paulson D; Cooper JA; Korducki L; Cassino C; Kesten S
Ann Intern Med; 2005 Sep; 143(5):317-26. PubMed ID: 16144890
[TBL] [Abstract][Full Text] [Related]
32. Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?
Burge S
Drugs; 2001; 61(11):1535-44. PubMed ID: 11577791
[TBL] [Abstract][Full Text] [Related]
33. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
34. Protocol for a systematic literature review and network meta-analysis of the clinical benefit of inhaled maintenance therapies in chronic obstructive pulmonary disease.
Lewis A; Axson EL; Potts J; Tarnowska R; Vioix H; Quint JK
BMJ Open; 2019 Feb; 9(2):e025048. PubMed ID: 30787090
[TBL] [Abstract][Full Text] [Related]
35. Critical Inhaler Handling Error Is an Independent Risk Factor for Frequent Exacerbations of Chronic Obstructive Pulmonary Disease: Interim Results of a Single Center Prospective Study.
Ahn JH; Chung JH; Shin KC; Choi EY; Jin HJ; Lee MS; Nam MJ; Lee KH
Int J Chron Obstruct Pulmon Dis; 2019; 14():2767-2775. PubMed ID: 31819409
[TBL] [Abstract][Full Text] [Related]
36. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
[TBL] [Abstract][Full Text] [Related]
37. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?
Tashkin DP
Curr Opin Pulm Med; 2005 Mar; 11(2):121-8. PubMed ID: 15699783
[TBL] [Abstract][Full Text] [Related]
38. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.
Cosío BG; Shafiek H; Iglesias A; Yanez A; Córdova R; Palou A; Rodriguez-Roisin R; Peces-Barba G; Pascual S; Gea J; Sibila O; Barnes PJ; Agusti A
Chest; 2016 Jul; 150(1):123-30. PubMed ID: 27107490
[TBL] [Abstract][Full Text] [Related]
39. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease.
Tatsumi K; Fukuchi Y;
J Am Geriatr Soc; 2007 Nov; 55(11):1884-6. PubMed ID: 17979906
[No Abstract] [Full Text] [Related]
40. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
